Canaccord Genuity restated their buy rating on shares of Sientra (NASDAQ:SIEN) in a research report released on Friday, January 5th. The firm currently has a $19.00 price objective on the medical instruments supplier’s stock.
Several other research firms also recently weighed in on SIEN. Stifel Nicolaus reiterated a hold rating and issued a $14.00 price target (up from $11.00) on shares of Sientra in a research report on Wednesday, September 27th. BidaskClub upgraded shares of Sientra from a sell rating to a hold rating in a research report on Friday, December 15th. Zacks Investment Research upgraded shares of Sientra from a sell rating to a hold rating in a research report on Tuesday, January 2nd. ValuEngine upgraded shares of Sientra from a sell rating to a hold rating in a research report on Sunday, December 31st. Finally, William Blair upgraded shares of Sientra from a market perform rating to an outperform rating in a research report on Wednesday, September 13th. One investment analyst has rated the stock with a sell rating, three have given a hold rating and four have given a buy rating to the company’s stock. The stock has an average rating of Hold and an average target price of $15.00.
Sientra (NASDAQ:SIEN) traded down $0.87 during trading hours on Friday, hitting $11.65. 303,600 shares of the stock were exchanged, compared to its average volume of 184,211. Sientra has a 1 year low of $7.20 and a 1 year high of $16.68. The company has a current ratio of 2.87, a quick ratio of 1.92 and a debt-to-equity ratio of 0.57. The stock has a market capitalization of $226.03, a PE ratio of -4.09 and a beta of -1.47.
A number of institutional investors and hedge funds have recently bought and sold shares of SIEN. Bamco Inc. NY grew its stake in Sientra by 109.3% during the second quarter. Bamco Inc. NY now owns 471,500 shares of the medical instruments supplier’s stock valued at $4,583,000 after acquiring an additional 246,183 shares in the last quarter. EAM Investors LLC purchased a new position in shares of Sientra in the 3rd quarter worth $3,018,000. Pura Vida Investments LLC purchased a new position in shares of Sientra in the 3rd quarter worth $2,892,000. State Street Corp purchased a new position in shares of Sientra in the 2nd quarter worth $1,449,000. Finally, Northern Trust Corp grew its stake in shares of Sientra by 449.4% in the 2nd quarter. Northern Trust Corp now owns 149,227 shares of the medical instruments supplier’s stock worth $1,451,000 after buying an additional 122,066 shares in the last quarter. 76.59% of the stock is owned by institutional investors.
COPYRIGHT VIOLATION WARNING: This piece was reported by BBNS and is owned by of BBNS. If you are viewing this piece on another publication, it was illegally stolen and republished in violation of U.S. and international copyright & trademark laws. The legal version of this piece can be read at https://baseballnewssource.com/markets/sientra-sien-given-buy-rating-at-canaccord-genuity/1820759.html.
Sientra Company Profile
Sientra, Inc is a medical aesthetics company. The Company’s primary products are silicone gel breast implants for use in breast augmentation and breast reconstruction procedures, which it offers in over 190 variations of shapes, sizes and textures. The Company sells its breast implants and breast tissue expanders, or breast products to plastic surgeons.
Receive News & Ratings for Sientra Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sientra and related companies with MarketBeat.com's FREE daily email newsletter.